NCT05751798 - Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions

Solid Advanced TumorLymphomaNSCLC (Non-small Cell Lung Cancer)

Interventions

DRUG

Part A: OSE-279 100mg

Human IgG4 mAb against PD-1

DRUG

Part A: OSE-279 300mg

Human IgG4 mAb against PD-1

DRUG

Part A: OSE-279 600mg

Human IgG4 mAb against PD-1

DRUG

Part B: OSE-279 600 mg and OSE2101

OSE-279: OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine

DRUG

Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive

OSE-279: Human IgG4 mAb against PD-1 OSE2101: Cancer vaccine

DRUG

Part C: OSE-279 600 mg - HLA-A2 positif

OSE-279: Human IgG4 mAb against PD-1

DRUG

Part C: OSE-279 600 mg - HLA-A2 negative

OSE-279: Human IgG4 mAb against PD-1

Trial Locations (10)

1070

RECRUITING

Institut Jules Bordet, Anderlecht

2901

NOT_YET_RECRUITING

Hospital Regional Universitario de Málaga, Málaga

11013

NOT_YET_RECRUITING

Antwerp University Hospital, Edegem

31059

RECRUITING

Oncopole, Toulouse

35000

COMPLETED

Centre Eugène Marquis, Rennes

44805

RECRUITING

Institut de Cancerologie de l'Ouest, Saint-Herblain

69373

RECRUITING

Centre Léon Bérard, Lyon

75014

RECRUITING

Hopital Saint Joseph, Paris

94805

RECRUITING

Institut Gustave Roussy, Villejuif

Unknown

ACTIVE_NOT_RECRUITING

University Hospital A Coruña Biomedical Research Institute (INIBIC), A Coruña